Catalent (CTLT) has contracts to make three of the leading Covid-19 vaccine candidates.
In the company's June-quarter earnings release early Monday, CEO John Chiminski said a shift to more innovative technologies is "reflected in more than 50 Covid-19-related program wins."
Among other gains, Chiminski said Catalent has built its cash position to more than $950 million, "positioning us to continue our growth investments."